NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against Regado Biosciences, Inc. (NASDAQ:RGDO) resulting from allegations that the Company may have made false and misleading disclosures concerning its Phase 3 clinical trials.
On July 2, 2014 Regado Biosciences announced the suspension of its Phase 3 study of its anticoagulant drug, REG1 (now known as Revolixys Kit), pending a review of potential safety problems. In its announcement, Regado Biosciences stated: “that the Data Safety Monitoring Board, or DSMB, has initiated an unplanned review of data from the Company's Phase 3 trial of Revolixys Kit (previously known as REG1), entitled REGULATE-PCI, and that patient enrollment has been paused in the REGULATE-PCI trial until the DSMB has completed its analysis and communicated its recommendations.” Regado Biosciences further explained that: “[t]he DSMB will conduct a full analysis of safety and treatment benefit-risk ratio of all patients enrolled to date (3234) with a focus on serious adverse events related to allergic reactions.” Upon this news, shares of Regado Biosciences fell dramatically, damaging investors.
The Rosen Law Firm is preparing a class action lawsuit on behalf of Regado Biosciences investors. If you purchased Regado Biosciences securities prior to July 3, 2014, you may visit the website at http://rosenlegal.com to join the action. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.